Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies

Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key

Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and

Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'

New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based

Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborations

Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease

Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore

Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse

Neurophet Presented Three Research Abstracts on Personalized tDCS at International Brain Stimulation Conference

- Showcased core technology and products for personalized tDCS at the conference in Kobe, Japan - Presented